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ABSTRACT
Chikungunya virus (CHIKV) is a mosquito-borne alphavirus that has reemerged to cause profound epidemics of fever,
rash, and arthralgia throughout sub-Saharan Africa, Southeast Asia, and the Caribbean. Like other arthritogenic alphavi-
ruses, mechanisms of CHIKV pathogenesis are not well defined. Using the attenuated CHIKV strain 181/25 and virulent
strain AF15561, we identified a residue in the E2 viral attachment protein that is a critical determinant of viral replication
in cultured cells and pathogenesis in vivo. Viruses containing an arginine at E2 residue 82 displayed enhanced infectivity
in mammalian cells but reduced infectivity in mosquito cells and diminished virulence in a mouse model of CHIKV dis-
ease. Mice inoculated with virus containing an arginine at this position exhibited reduced swelling at the site of inocula-
tion with a concomitant decrease in the severity of necrosis in joint-associated tissues. Viruses containing a glycine at E2
residue 82 produced higher titers in the spleen and serum at early times postinfection. Using wild-type and glycosamino-
glycan (GAG)-deficient Chinese hamster ovary (CHO) cell lines and soluble GAGs, we found that an arginine at residue 82
conferred greater dependence on GAGs for infection of mammalian cells. These data suggest that CHIKV E2 interactions
with GAGs diminish dissemination to lymphoid tissue, establishment of viremia, and activation of inflammatory re-
sponses early in infection. Collectively, these results suggest a function for GAG utilization in regulating CHIKV tropism
and host responses that contribute to arthritis.
IMPORTANCE
CHIKV is a reemerging alphavirus of global significance with high potential to spread into new, immunologically naive
populations. The severity of CHIKV disease, particularly its propensity for chronic musculoskeletal manifestations, em-
phasizes the need for identification of genetic determinants that dictate CHIKV virulence in the host. To better understand
mechanisms of CHIKV pathogenesis, we probed the function of an amino acid polymorphism in the E2 viral attachment
protein using a mouse model of CHIKV musculoskeletal disease. In addition to influencing glycosaminoglycan utilization,
we identified roles for this polymorphism in differential infection of mammalian and mosquito cells and targeting of
CHIKV to specific tissues within infected mice. These studies demonstrate a correlation between CHIKV tissue tropism
and virus-induced pathology modulated by a single polymorphism in E2, which in turn illuminates potential targets for
vaccine and antiviral drug development.
Chikungunya virus (CHIKV) is a mosquito-borne alphavirusthat has reemerged to cause sudden and severe epidemics
throughout sub-Saharan Africa, Southeast Asia, and the Carib-
bean. CHIKV infection causes a rheumatic disease principally
characterized by an abrupt onset of fever, rash, headache, and
debilitating polyarthralgia and myalgia (1, 2). Although acute
symptoms usually subside within 1 to 2 weeks, chronic joint pain
and inflammation occur in many patients for months or years
after the initial infection (3–7). The occurrence of chronic arthritis
is highly variable, ranging between 15 and 70% of infected indi-
viduals depending on the specific study cohort and observed most
frequently in the elderly and persons with comorbidities (7).
Since 2004, the geographic distribution of CHIKV has increased
significantly, reaching immunologically naive populations in islands
of the Indian Ocean, Europe, and the Caribbean (8–13). These epi-
demics are noteworthy for more severe clinical manifestations, in-
cluding encephalopathy, hepatitis, meningoencephalitis, and ocular
disease and represent the first documented cases of fatal infection
(14–16). Currently, there are no licensed CHIKV vaccines or antiviral
therapies for infected individuals, and only supportive care for clini-
cal symptoms is available.
CHIKV is an Old World alphavirus and member of the Semliki
Forest antigenic complex along with the closely related O’nyong-
nyong virus (ONNV), Ross River virus (RRV), and Semliki Forest
virus (SFV) (17). The alphavirus genome consists of a single, pos-
itive-sense RNA molecule approximately 12 kb in length that con-
tains two open reading frames (18, 19). The first open reading
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frame encodes four nonstructural proteins (nsP1 to nsP4) that
form the replicase complex and mediate synthesis of additional
copies of the viral genome and the subgenomic RNA (17–19). The
subgenomic, second open reading frame encodes a polyprotein
containing three major structural proteins, capsid, pE2, and E1,
and the small peptides, 6K and TF (17, 19–22). Following transla-
tion of the subgenomic RNA, the capsid protein is autoproteolyti-
cally cleaved from the polyprotein (18, 23). The remainder is
transported through the endoplasmic reticulum (ER) and Golgi
apparatus where the 6K peptide is liberated by cellular proteases
and the E1 and pE2 proteins are glycosylated (20, 24). During
egress, the cellular protease furin cleaves pE2 to release the E3
peptide and generate the mature heterodimer of E1 fusion and E2
attachment proteins (25–27). E1-E2 heterodimers associate as
trimers and stud the host-derived lipid bilayer that surrounds the
icosahedral capsid (27). The structural proteins encapsidate the
viral genome, forming progeny virions near the plasma mem-
brane, which bud from the host cell to infect neighboring cells and
disseminate throughout the host (28).
A live, attenuated CHIKV vaccine was developed by passaging
a clinical isolate from Thailand, strain AF15561, extensively in
mammalian cell culture to produce a highly attenuated virus,
strain 181/25 (29, 30). Strains AF15561 and 181/25 differ at only
10 nucleotide positions and 5 amino acid positions across the
genome. A previous study identified two polymorphisms in the E2
attachment protein, T12I and G82R, as important mediators of
virus strain 181/25 attenuation in both infant CD1 and immuno-
compromised mice (31). Accumulation of positively charged res-
idues within E2 as a consequence of cell culture passage has been
demonstrated for other alphaviruses to confer binding to nega-
tively charged glycosaminoglycans (GAGs) such as heparan sul-
fate (32–36). We and others have found that strain 181/25 inter-
acts with GAGs to infect host cells and that this interaction is
strengthened through the G82R polymorphism in E2 (37, 38).
Given the minimal sequence divergence displayed by strains
181/25 and AF15561, it is not known whether they differ in GAG
utilization, nor is it clear whether GAG utilization is the sole
mechanism that mediates CHIKV 181/25 attenuation.
Heparan sulfate-binding viruses often exhibit reduced viral
dissemination and attenuation for disease in vivo (34, 39–42).
However, such viruses can show increased virulence depending
on the route of inoculation, as demonstrated for certain strains of
eastern equine encephalitis virus (EEEV) (43, 44). A strategy to
introduce attenuating heparan sulfate-binding residues within the
CHIKV E2 attachment protein has been established as a model for
CHIKV vaccine development (45). Wild-type CHIKV strain
LR2006 OPY1 (LR) induced significantly less footpad swelling and
proinflammatory cytokine production following substitution of
E2 Gly82 with arginine and Glu79 with lysine, the latter of which
was identified following serial passage in cell culture (45). Intro-
duction of either substitution enhanced sensitivity to blockade of
infection by soluble heparin or salt disruption of ionic interactions
(45), suggesting that viruses attenuated by virtue of these muta-
tions exhibit increased dependence on GAGs for infection. How-
ever, the roles of E2 residue 82 in CHIKV-induced arthritis and
viral tropism are not fully understood. Furthermore, mechanisms
by which specific CHIKV residues influence viral pathogenesis
remain to be elucidated.
In this study, we defined the contribution of sequence poly-
morphisms displayed by strains 181/25 and AF15561 to CHIKV
pathogenesis using a mouse model of CHIKV-induced arthritis.
We engineered a panel of CHIKV variants containing these poly-
morphisms in the genetic background of each parental strain and
screened these viruses for differences in infectivity in mammalian
and mosquito cells prior to testing in vivo. We found that E2
residue 82 is a determinant of infectivity in mammalian and mos-
quito cell culture and contributes to CHIKV-induced pathology,
including footpad swelling and inflammation and necrosis in the
metatarsal muscle ipsilateral to the site of inoculation. In addition,
this residue mediates viral dissemination to the spleen and estab-
lishment of viremia. Viruses containing an arginine at E2 residue
82 exhibit increased dependence on GAGs for infection of mam-
malian cells and are more attenuated for musculoskeletal disease.
We conclude that CHIKV utilization of GAGs alters viral tropism,
tissue inflammation, and tissue injury induced during infection,
resulting in attenuated CHIKV disease.
MATERIALS AND METHODS
Cells, viruses, and antibodies. Baby hamster kidney cells (BHK-21;
ATCC CCL-10) were maintained in alpha minimal essential medium
(MEM; Gibco) supplemented to contain 10% fetal bovine serum (FBS;
Gibco), 10% tryptose phosphate (TP), 2 mM L-glutamine (Gibco), 100
U/ml of penicillin, 100 g/ml of streptomycin (Gibco), and 25 ng/ml of
amphotericin B (Sigma). Vero cells (ATCC CCL-81) were maintained in
MEM supplemented to contain 5% FBS, L-glutamine, penicillin, strep-
tomycin, and amphotericin B. C6/36 cells were maintained in Leibovitz’s
L-15 medium (Gibco) supplemented to contain 10% FBS, 10% TP, L-glu-
tamine, penicillin, streptomycin, and amphotericin B. Chinese hamster
ovary (CHO) CHO-K1 and CHO-pgsA745 cells (46) were maintained in
F-12 nutrient mixture (Gibco) supplemented to contain 10% FBS, L-glu-
tamine, penicillin, streptomycin, and amphotericin B. CHO-K1 and
CHO-pgsA745 cell lines were provided by Benhur Lee (University of Cal-
ifornia, Los Angeles).
The CHIKV 181/25 infectious clone plasmid was generated as de-
scribed previously (47). The CHIKV AF15561 infectious clone and variant
clone plasmids were generated using site-directed mutagenesis of the
181/25 infectious clone plasmid.
CHIKV-specific polyclonal antiserum was obtained from the ATCC
(VR-1241AF). CHIKV E2-specific monoclonal antibodies (MAbs) CHK-
152 and CHK 48-G8 were provided by Michael Diamond (Washington
University).
Site-directed mutagenesis. Single-amino-acid substitutions (nsP1
I301T, E2 I12T, E2 R82G, 6K P42C, and E1 V404A) were generated by
site-directed mutagenesis of the 181/25 infectious clone plasmid using
KOD Hot Start DNA polymerase (Novagen). All five amino acid substi-
tutions were introduced into the 181/25 plasmid to generate the AF15561
infectious clone plasmid. Reciprocal, single-amino-acid substitutions
(nsP1 T301I, E2 T12I, E2 G82R, 6K C42P, and E1 A404V) were generated
similarly in the AF15561 infectious clone plasmid. cDNA from each clone
was sequenced to verify that only the desired mutations were introduced.
Generation of virus stocks from infectious clone plasmids. Infec-
tious clone plasmids were linearized and transcribed in vitro using
mMessage mMachine SP6 transcription kits (Ambion). BHK-21 cells
were electroporated with viral RNA and incubated at 37°C for 24 h. Su-
pernatants containing progeny virus were collected from electroporated
cells and stored at 80°C. For some experiments, supernatants were pu-
rified by ultracentrifugation through a 20% sucrose cushion in TNE buf-
fer (50 mM Tris-HCl [pH 7.2], 0.1 M NaCl, and 1 mM EDTA) at
115,000  g in a Beckman 32Ti rotor. Virus pellets were resuspended in
virus diluent buffer (VDB) (RPMI medium with HEPES [Gibco] and 1%
FBS) and stored at 80°C. Viral titers were determined by plaque assay
using Vero cells. All experiments with virus were performed using bio-
safety level 3 conditions.
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CHIKV infectivity assay. Vero, C6/36, CHO-K1, or CHO-pgsA745
cells seeded onto no. 2 glass coverslips (VWR) in 24-well plates or in
96-well plates (Costar) were adsorbed with CHIKV strains in VDB at a
multiplicity of infection (MOI) of 1 (Vero and C6/36) or 10 (CHO-K1 and
CHO-pgsA745) PFU/cell at 37°C (Vero, CHO-K1, and CHO-pgsA745) or
30°C (C6/36) for 1 h. The inoculum was removed, complete medium was
added, and cells were incubated at 37°C or 30°C for an additional hour.
The medium was then supplemented to contain 20 mM ammonium chlo-
ride to prevent subsequent rounds of infection. After incubation at 37°C
or 30°C for 24 h, cells were fixed with ice-cold 100% methanol, washed
with phosphate-buffered saline (PBS), and incubated with PBS contain-
ing 5% FBS and 0.1% Triton X-100 (TX) at room temperature for 1 h. The
cells were incubated with CHIKV-specific polyclonal antiserum (1:1,500)
in PBS with FBS and TX at 4°C overnight. The cells were washed three
times with PBS and incubated with Alexa Fluor 488-labeled anti-mouse
IgG (1:1,000) in PBS with FBS and TX at room temperature for 2 h. The
cells were also incubated with 4=,6-diamidino-2-phenylindole (DAPI; In-
vitrogen) to stain nuclei. The cells and nuclei were visualized by indirect
immunofluorescence using an Axiovert 200 fluorescence microscope
(Zeiss). CHIKV-positive cells were enumerated in three fields of view with
each field of view containing at least 100 cells for triplicate samples. For
some experiments, cells were visualized using an ImageXpress Micro XL
imaging system (Molecular Devices) at the Vanderbilt High-Throughput
Screening Facility. Total and CHIKV-infected cells were quantified using
MetaXpress software (Molecular Devices) in four fields of view containing
at least 100 cells per field of view for triplicate samples. The number of
CHIKV-positive cells was normalized to the total number of cells per field
to determine the percentage of infected cells.
Assessment of CHIKV replication by plaque assay. Vero or C6/36
cells were adsorbed with CHIKV strains in VDB at an MOI of 0.01 PFU/
cell at 37°C (Vero) or 30°C (C6/36) for 1 h. The inoculum was removed,
cells were washed with PBS, and complete medium was added. After in-
cubation at 37°C or 30°C for various intervals, 10% of the cell supernatant
was collected and replaced with fresh medium. Viral titers in culture su-
pernatants were determined by plaque assay using Vero cells.
Real-time quantitative RT-PCR. RNA was isolated using a PureLink
RNA minikit (Life Technologies). The number of viral genomes/ml for
each virus stock was quantified using the qScript XLT one-step reverse
transcription-quantitative PCR (RT-qPCR) ToughMix kit (Quanta Bio-
sciences) as described previously (38). CHIKV sequence-specific forward
(CHIKVfor [874 5=-AAAGGGCAAGCTTAGCTTCAC-3=]) and reverse
(CHIKVrev [961 5=-GCCTGGGCTCATCGTTATTC-3=]) primers were
used with an internal fluorogenic probe (CHIKVprobe [899 5=-6-car-
boxyfluorescein{dFAM}-CGCTGTGATACAGTGGTTTCGTGTG-black
hole quencher {BHQ}-3=; Biosearch Technologies). To relate threshold
cycle (CT) values to copies of genomic RNA, standard curves were gener-
ated from 10-fold dilutions, from 101 to 1010 copies, of in vitro-tran-
scribed genomic 181/25 RNA.
CHIKV binding assay. Vero cells were adsorbed in suspension with
3  1010 genomes of various virus strains in VDB at 4°C for 30 min. The
cells were washed with incomplete medium and PBS and fixed in PBS with
1% electron microscopy (EM)-grade paraformaldehyde (Electron Mi-
croscopy Sciences). The cells were washed with fluorescence-activated cell
sorting (FACS) buffer (PBS with 2% FBS) and incubated with CHIKV
E2-specific MAb CHK-152 (1:1,000) in FACS buffer at 4°C for 30 min.
The cells were incubated with Alexa Fluor 488-labeled anti-mouse IgG
(1:1,000) in FACS buffer at 4°C for 30 min and analyzed using a BD LSRII
flow cytometer. Cell staining was quantified using FlowJo software (Tree
Star).
Inhibition of CHIKV infection with soluble glycosaminoglycans.
Virus was pretreated with soluble heparin (Sigma) or bovine serum albu-
min (BSA) (Sigma) at 4°C for 30 min. Vero cells were adsorbed with
pretreated virus strains at an MOI of 1 PFU/cell at 37°C for 2 h. The
inoculum was removed, and complete medium supplemented to contain
20 mM ammonium chloride was added to prevent subsequent rounds of
infection. After incubation at 37°C for 24 h, cells were fixed and incubated
with CHIKV-specific polyclonal antiserum and DAPI to detect nuclei.
Infection was scored by indirect immunofluorescence. CHIKV-positive
cells were enumerated in three fields of view for triplicate samples and
normalized to the number of total cells per field.
Heparin-agarose binding assay. Heparin-conjugated agarose or un-
conjugated agarose beads were incubated with 5  109 genomes of each
virus at 4°C for 30 min as described previously (38). The beads were
washed with VDB containing 0.02% Tween 20, and beads or input virus
were resuspended in sample buffer (50 mM Tris-HCl [pH 6.8], 2% [wt/
vol] sodium dodecyl sulfate [SDS], 1% -mercaptoethanol, 10% [vol/vol]
glycerol, 0.04% [wt/vol] bromophenol blue) and boiled for 10 min. Sam-
ples were resolved by SDS-polyacrylamide gel electrophoresis (PAGE) in
10% polyacrylamide gels (Bio-Rad) and transferred to an Immun-Blot
polyvinylidene difluoride (PVDF) membrane (Bio-Rad). The membranes
were incubated with Tris-buffered saline (TBS) containing 5% milk at
room temperature for 1 h followed by incubation with CHIKV-specific
MAb CHK 48-G8 (1:2,000) in TBS with 0.1% Tween 20 (TBS-T) at 4°C
overnight. The membranes were washed three times with TBS-T and in-
cubated with IRDye 750 CW-labeled goat anti-mouse IgG (1:5,000; LI-
COR) in TBS-T at room temperature for 2 h. The membranes were
washed three times with TBS-T and once with TBS, and CHIKV-specific
signal was detected using an Odyssey imaging system (LI-COR).
Infection of mice. C57BL/6J mice were obtained from The Jackson
Laboratory to establish breeding colonies. Mice (20 to 22 days old) were
inoculated in the left rear footpad with 103 PFU of virus in PBS containing
1% bovine calf serum (BCS) in a 10-l volume. Mock-infected animals
received diluent alone. Mice were monitored for clinical signs of disease
and weighed at 24-h intervals. At various intervals following infection,
mice were euthanized by isoflurane overdose, blood was collected by car-
diac puncture, and mice were perfused by intracardial injection of PBS.
Swelling of the feet of both hind limbs was quantified using calipers to
measure the height of the feet. For analysis of viral replication, tissues were
collected in PBS containing BCS, weighed, homogenized with a MagNA
lyser (Roche), and stored at 80°C. Viral titers in tissue homogenates
were determined by plaque assay using BHK-21 cells. For RNA analysis,
tissues were collected and homogenized in TRIzol reagent (Life Technol-
ogies).
Animal husbandry and experiments were performed in accordance
with all University of Colorado School of Medicine Institutional Animal
Care and Use Committee guidelines. All mouse studies were performed
using biosafety level 3 conditions.
Histological analysis. At day 7 postinoculation, mice were euthanized
and perfused by intracardial injection of 4% paraformaldehyde (PFA)
(pH 7.3). Tissues were resected and incubated in PFA at 4°C for at least 72
h. Fixed tissues were embedded in paraffin, and 5-m sections were
stained with hematoxylin and eosin (H&E) to assess histopathologic
changes. Tissues were scored by an observer in a blind manner (unaware
of the conditions of the experiment) for the presence, distribution, and
severity of histologic lesions. For all tissue changes, the following scoring
system was used: 0, no lesions; 1, minimal, 0 to 24% of tissue affected; 2,
mild, 25 to 49% of tissue affected; 3, moderate, 50 to 75% of tissue af-
fected; 4, marked, 75% of tissue affected.
Analysis of sequence reversion. RNA was isolated using a PureLink
RNA minikit (Life Technologies). cDNA was generated using the Super-
Script III first-strand kit (Life Technologies) with random hexamers and
used for PCR amplification by KOD polymerase (Novagen) with CHIKV
E2 sequence-specific forward (CHIKVE2for [8336 5=-GGGCCGAAGAG
TGGAGTCTT-3=]) and reverse (CHIKVE2rev [9089 5=-GACACCCCTG
ATCGCACATT-3=]) primers. Amplicons were cloned into a TOPO TA
vector (Life Technologies) and sequenced over the mutagenized region of
the E2 open reading frame.
Statistical analysis. Mean values for at least duplicate experiments
were compared using an unpaired Student’s t test, one-way analysis of
variance (ANOVA) followed by Bonferroni’s posthoc test, or Kruskal-
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Wallis analysis followed by Dunn’s posthoc test (GraphPad Prism). P
values of 	0.05 were considered to be statistically significant.
RESULTS
E2 residue 82 is a determinant of CHIKV infectivity in mamma-
lian cell culture. For many viruses, serial passage in mammalian
cells enhances viral replicative capacity in cell culture (33, 48–53).
To determine whether passage of CHIKV strain AF15561 to gen-
erate vaccine strain 181/25 resulted in enhanced replicative capac-
ity, cells were infected with either strain AF15561 or 181/25, and
viral titers in culture supernatants were determined by plaque as-
say over an infectious time course. Relative to strain AF15561,
strain 181/25 reached higher titers in several cell lines, including
Vero, BHK-21, HeLa, and human brain microvascular endothelial
cells (data not shown). These results suggest that strain 181/25 has
adapted to mammalian cell culture as a result of cell culture pas-
sage, consistent with observations for other passaged viruses.
Virus strains 181/25 and AF15561 differ at five nonsynony-
mous nucleotides and five synonymous nucleotides across the ge-
nome. Polymorphic positions resulting in coding changes in
181/25 are in the nsP1 (T301I), E2 (T12I and G82R), 6K (C42P),
and E1 (A404V) proteins (Fig. 1). To define residues that contrib-
ute to the replication and infectivity differences observed between
strains 181/25 and AF15561, Vero cells were infected at an MOI of
1 PFU/cell with either of the parental strains or viruses containing
individual polymorphic residues in the reciprocal genetic back-
ground. The percentage of infected cells in each case was quanti-
fied after a single round of infection by indirect immunofluores-
cence (Fig. 2A). As expected, virus strain 181/25 infected a
significantly greater percentage of cells than did virus strain
AF15561. Substitution of an arginine at E2 residue 82 in the
AF15561 background enhanced infectivity to levels even greater
than those observed for strain 181/25. Concordantly, substitution
of a glycine at E2 residue 82 in the 181/25 background significantly
diminished 181/25 infectivity. Interestingly, substituting an iso-
leucine at E2 residue 12 in the AF15561 background further de-
creased infectivity relative to AF15561. Introducing any of the
other heterologous changes in either background had no effect on
infectivity in these cells. To understand how these findings might
compare to previous studies with these viruses in mice, the paren-
tal and variant viruses were used to infect murine L929 and NIH
3T3 cell lines. As observed in experiments using Vero cells, sub-
stitution of an arginine at E2 residue 82 in the AF15561 back-
ground enhanced infectivity, whereas substitution of a glycine at
E2 residue 82 in the 181/25 background significantly diminished
infectivity in these murine cell lines (data not shown). These data
suggest that an arginine at residue 82 in the E2 protein confers the
enhanced infectivity observed for strain 181/25 in mammalian
cells.
Because these virus strains differed substantially in infectivity
of Vero cells, we quantified the genome/PFU and genome/fluores-
cent-focus unit (FFU) ratios for each strain (Table 1). In Vero
cells, parental strains AF15561 and 181/25 had genome/PFU ra-
tios of 6,598 and 176, respectively. Similarly, strains AF15561 and
181/25 had genome/FFU ratios of 9.497  107 and 8.0  105,
respectively. Viral variants containing residues from strain 181/25
FIG 1 Schematic depiction of polymorphic residues in CHIKV strains
AF15561 and 181/25. Distribution of amino acid polymorphisms between
strains AF15561 and 181/25 across the 12-kb genome. Numbers correspond
to the amino acid positions within each protein.
FIG 2 Residue 82 of the E2 attachment protein is a determinant of CHIKV
infectivity in mammalian cells. (A) Vero cells were adsorbed with CHIKV
strains AF15561 (AF), 181/25 (181), or the variant viruses shown at an MOI of
1 PFU/cell and incubated for 24 h in medium containing 20 mM NH4Cl. The
cells were stained with CHIKV-specific antiserum and DAPI to detect nuclei
and imaged by fluorescence microscopy. Results are presented as percent in-
fected cells for triplicate experiments. Error bars indicate standard errors of the
means. (B) Vero cells were adsorbed with virus strain AF15561, 181/25,
AF15561 E2 G82R, or 181/25 E2 R82G at an MOI of 0.01 PFU/cell. At the times
shown, viral titers in culture supernatants were determined by plaque assay
using Vero cells. Results are presented as the mean viral titers for triplicate
samples. Error bars indicate standard deviations. Titers of virus strains
AF15561 and AF15561 E2 G82R were significantly different at 6, 12, and 18 h
postinfection, and titers of virus strains 181/25 and 181/25 E2 R82G were
significantly different at 12, 18, 24, 30, and 36 h postinfection. (C) Vero cells
were adsorbed with 3  1010 genomes of wild-type (WT) virus strain
AF15561, 181/25, AF15561 E2 G82R, or 181/25 E2 R82G for 30 min. After
30-min incubation, cells were stained with CHIKV E2-specific MAb, and vi-
rus-bound cells were quantified by flow cytometry. Results are presented as
percent bound cells for triplicate experiments normalized to cell autofluores-
cence in the absence of CHIKV MAb. No CHIKV-bound cells were detected
for virus strain 181/25 E2 R82G. Error bars indicate standard deviations. Val-
ues that are significantly different, as determined by ANOVA, followed by
Bonferroni’s posthoc test (A and C) and Student’s t test (B), are indicated by
asterisks as follows: , P 	 0.05; , P 	 0.01; , P 	 0.001.
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in the AF15561 background had reduced genome/PFU and ge-
nome/FFU ratios compared to those of parental strain AF15561.
Interestingly, introducing the E2 G82R substitution resulted in
the most modest reduction in genome/PFU ratio, but the greatest
reduction in genome/FFU ratio. In contrast, introducing the E2
R82G substitution in the 181/25 background resulted in increased
genome/PFU and genome/FFU ratios, which were the most dra-
matic increases of any of the viral variants with AF15561 residues
in the 181/25 background. Thus, the E2 82 polymorphism serves
as a key determinant of CHIKV infectivity in mammalian cell
culture.
To determine whether E2 residue 82 contributes to the pro-
duction of infectious virus over multiple rounds of infection, Vero
cells were infected at an MOI of 0.01 PFU/cell, and viral titers in
culture supernatants were determined by plaque assay at 6-h in-
tervals (Fig. 2B). Compared with titers of AF15561, titers of
AF15561 E2 G82R were increased 10-fold by 6 h postinfection,
7-fold by 12 h postinfection, and 40-fold by 18 h postinfection.
Compared with titers of virus strain 181/25, titers of 181/25 E2
R82G were reduced 145-fold by 18 h postinfection, 60-fold by 24
h postinfection, and 68-fold by 30 h postinfection. Taken to-
gether, these data indicate that E2 residue 82 influences both ini-
tial and subsequent rounds of CHIKV infection.
Because this determinant of CHIKV infectivity resides in the
viral attachment protein, we tested whether E2 residue 82 in-
fluences binding to host cells. For these experiments, Vero cells
were adsorbed with each parental strain and the reciprocal E2
82 variant strains, and the percentage of virus-bound cells was
quantified using flow cytometry (Fig. 2C). A significantly
greater proportion of cells were bound by strain 181/25 than by
strain AF15561. In agreement with the infectivity data, intro-
ducing the E2 G82R substitution in the AF15561 background
significantly enhanced cell attachment. In contrast, introduc-
ing the E2 R82G polymorphism in the 181/25 background re-
duced cell binding to undetectable levels. These data suggest
that an arginine at position 82 in the E2 attachment protein is
required for the enhanced binding and infectivity observed for
strain 181/25 in mammalian cells.
E2 residue 82 contributes to CHIKV infectivity in mosquito
cells. To determine whether an arginine at E2 residue 82 affects
infection and replication in invertebrate cells, we tested the paren-
tal and reciprocal E2 82 variant strains for infection and replica-
tion in mosquito cells (Fig. 3). Aedes albopictus C6/36 cells were
infected at an MOI of 1 PFU/cell, and the percentage of infected
cells was quantified after a single round of infection by indirect
immunofluorescence (Fig. 3A). In sharp contrast to our findings
using mammalian cells, strain 181/25 infected significantly fewer
C6/36 cells relative to strain AF15561, and substitution of a glycine
at E2 residue 82 in the 181/25 background significantly increased
181/25 infectivity in these cells. However, substitution of an argi-
nine at E2 residue 82 in the AF15561 background did not signifi-
cantly diminish C6/36 infection. Surprisingly, only substitution of
isoleucine for threonine at residue 12 in AF15561 E2 was sufficient
to reduce infection in these cells, albeit not to the levels observed
for strain 181/25. Additionally, AF15561 E2 G82R had a similar
genome/FFU ratio compared to that of AF15561, whereas substi-
tutions at the other polymorphic sites with residues from strain
181/25 decreased the genome/FFU ratio. Together, these data in-
dicate that the residue at E2 position 82 provides a fitness advan-
tage for CHIKV infectivity depending on the host cell species.
To assess the role of E2 residue 82 in the production of infec-
tious virus from mosquito cells, C6/36 cells were infected at an
MOI of 0.01 PFU/cell, and viral titers in culture supernatants were
determined at 6-h intervals (Fig. 3B). Relative to titers of virus
strain 181/25, titers of 181/25 E2 R82G were increased 29-fold by
12 h postinfection, 8-fold by 18 h postinfection, and 13-fold by 24
h postinfection. However, relative to titers of virus strain
AF15561, there was no decrease in viral titers when an arginine
was introduced at E2 82 in the AF15561 strain. These data indicate
that E2 Gly82 in the genetic background of strain 181/25 enhances
infection of mosquito cells. However, other polymorphisms ex-
hibited by these strains appear to contribute to the enhanced in-
fectivity of AF15561 in mosquito cells in addition to E2 Gly82.
E2 residue 82 influences utilization of glycosaminoglycans.
To understand mechanisms by which E2 residue 82 influences
CHIKV attachment to mammalian cells, we next investigated the
dependence of virus strains 181/25 and AF15561 on GAGs for
infectivity. Wild-type CHO-K1 and GAG-deficient CHO-




Genome/FFU ratioc ( 104) in:
RatiodCHO-K1 cells CHO-pgsA745 cells
AF15561 647 1,578 11,795 7.47
AF15561 E2
G82R
498 867 20,494 23.65
181/25 92 310 2,376 7.67
181/25 E2
R82G
316 1,862 8,155 4.38
a Infectivity of virus strains measured in genome equivalents.
b Genome copy numbers were determined by real-time quantitative PCRs conducted in
triplicate. The number of PFU was determined by plaque assay using Vero cells for
three independent replicates for each virus strain.
c Fluorescent-focus units (FFU) were determined by indirect immunofluorescence in
triplicate for at least two independent experiments.
d Ratio of the genome/FFU ratio in CHO-pgsA745 cells to the genome/FFU ratio in
CHO-K1 cells.






Vero cells C6/36 cells
AF15561 6,598 9,497 980
181/25 176 80 182
AF15561 nsP1 T301I 1,718 2,173 250
AF15561 E2 T12I 1,107 7,621 344
AF15561 E2 G82R 5,656 760 841
AF15561 6K C42P 3,057 4,529 436
AF15561 E1 A404V 4,067 6,255 586
181/25 nsP1 I30T 1,005 455 381
181/25 E2 I12T 99 35 45
181/25 E2 R82G 2,858 9,783 517
181/25 6K P42C 44 17 16
181/25 E1 V404A 121 46 27
a Infectivity of virus strains measured in genome equivalents.
b Genome copy numbers were determined by real-time quantitative PCRs conducted in
triplicate. The number of PFU was determined by plaque assay using Vero cells for
three independent replicates for each virus strain.
c Fluorescent-focus units (FFU) were determined by indirect immunofluorescence in
triplicate for at least two independent experiments.
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pgsA745 cells were infected with purified 181/25, AF15561, 181/25
E2 R82G, or AF15561 E2 G82R at an MOI of 10 PFU/cell. The
percentage of infected cells for each virus was quantified after a
single round of infection by indirect immunofluorescence (Fig.
4A). The CHO-pgsA745 cells were significantly less susceptible to
infection by all four viruses relative to infection of CHO-K1 cells
(P 	 0.0001 for virus strains 181/25 and AF15561, P 	 0.001 for
AF15561 E2 G82R, and P 	 0.05 for 181/25 E2 R82G). However,
the CHO-pgsA745 cells were significantly less susceptible to infec-
tion by strain 181/25 relative to strain AF15561. Substitution of E2
Gly82 with arginine in the AF15561 background was sufficient to
diminish infectivity in these cells to levels observed for strain 181/
25. Furthermore, substitution of E2 Arg82 with glycine in the
181/25 background was sufficient to increase infectivity and mit-
igate GAG dependence to levels observed for strain AF15561.
These data confirm that strain 181/25 is more dependent on GAGs
for infection than is AF15561 and that E2 residue 82 mediates this
dependence.
We also assessed infectivity by determining genome/PFU ra-
tios using Vero cells and genome/FFU ratios using both CHO-K1
and CHO-pgsA745 cells. We observed a similar trend in the ge-
nome/PFU values of purified stocks of the parental and variant
viruses used in these experiments. Strain AF15561 had higher ge-
nome/PFU ratios than strain 181/25 did in both cell lines, and
these differences once again segregated with E2 residue 82. Inter-
estingly, all strains had higher genome/FFU ratios in CHO-
pgsA745 cells than in the parental CHO-K1 cells. These data sup-
port the hypothesis that viruses containing an arginine at E2
residue 82 are less fit in GAG-deficient cells relative to their gly-
cine-containing counterparts.
On the basis of these and previously published findings (32–
36), the GAG dependence mediated by this residue likely occurs at
an early step in the infectious life cycle. Therefore, we reasoned
that soluble GAGs could act as competitive agonists to block in-
fectivity of GAG-dependent viruses. To test whether competition
with soluble GAGs inhibits infection, purified virus was incubated
with increasing concentrations of soluble heparin, a highly sul-
fated GAG, and adsorbed to Vero cells. The percentage of infected
cells was quantified after a single round of infection by indirect
immunofluorescence (Fig. 4B). Treatment with soluble heparin
resulted in a dose-dependent decrease in the percentage of in-
fected cells for all viruses tested. However, this decrease was most
substantial for strains 181/25 and AF15561 E2 G82R, for which
incubation with the highest concentration of heparin decreased
infectivity 15- and 24-fold, respectively. In contrast, incubation of
strains AF15561 and 181/25 E2 R82G with the same concentration
of heparin resulted in only a 4-fold decrease in infectivity. These
findings suggest that CHIKV strains containing an arginine at E2
residue 82 rely on GAGs for efficient cell attachment.
To determine whether the CHIKV strains used in our study
interact directly with GAGs, equivalent genome copies of purified
parental or variant viruses were incubated with either heparin-
conjugated or unconjugated agarose beads. Bound material was
resolved by SDS-PAGE and immunoblotted using an E2-specific
MAb to detect CHIKV particles (Fig. 4C, left). A significantly
greater proportion of strain 181/25 was bound by the heparin-
conjugated beads relative to the binding of strain AF15561. Sub-
stituting AF15561 E2 Gly82 with arginine increased the propor-
tion of this virus that was bound by the heparin-conjugated beads.
Concordantly, substituting strain 181/25 E2 Arg82 with glycine
decreased heparin binding. Intensities of the viral protein bands
from the particles bound to the heparin-conjugated beads were
quantified for three independent experiments and normalized to
the intensities of protein bands for input virus (Fig. 4C, right).
Approximately 35% and 37% of strains 181/25 and AF15561 E2
G82R, respectively, were captured by the heparin-agarose beads,
whereas only 13% and 16% of strains AF15561 and 181/25 E2
R82G, respectively, bound to heparin. These results suggest that
CHIKV virions interact directly with GAGs and that these inter-
actions are influenced by E2 residue 82.
CHIKV E2 residue 82 modulates virus-induced pathology.
We next investigated whether E2 residue 82 influences CHIKV
pathogenesis using a mouse model of CHIKV disease (54). In this
model, 3-week-old mice are inoculated subcutaneously in the left
rear footpad. Infected mice develop signs of disease similar to
those observed in humans infected with CHIKV, including swell-
ing of the feet and ankles, arthritis, myositis, and tenosynovitis.
Mice were inoculated with 103 PFU of strain 181/25, AF15561,
FIG 3 Residue 82 of the E2 attachment protein is a determinant of CHIKV
infectivity in mosquito cells. (A) C6/36 mosquito cells were adsorbed with
CHIKV strains AF15561 and 181/25 or the variant viruses shown at an MOI of
1 PFU/cell and incubated for 24 h in medium containing 20 mM NH4Cl. The
cells were stained with CHIKV-specific antiserum and DAPI to detect nuclei
and imaged by fluorescence microscopy. Results are presented as percent in-
fected cells for quadruplicate experiments. Error bars indicate standard errors
of the means. (B) C6/36 cells were adsorbed with virus strain AF15561, 181/25,
AF15561 G82R, or 181/25 E2 R82G at an MOI of 0.01 PFU/cell. At the times
shown, viral titers in culture supernatants were determined by plaque assay
using Vero cells. Results are presented as the mean viral titers for triplicate
samples. Error bars indicate standard deviations. The titers of virus strains
181/25 and 181/25 E2 R82G were significantly different at 12, 18, and 24 h
postinfection. Values that are significantly different, as determined by
ANOVA, followed by Bonferroni’s posthoc test (A) and Student’s t test (B), are
indicated by asterisks as follows: , P 	 0.01; , P 	 0.001.
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181/25 E2 R82G, or AF15561 E2 G82R, and virulence was as-
sessed by weight gain and swelling of feet (Fig. 5). Mice infected
with virus strain AF15561 gained less weight than mice infected
with virus strain 181/25, indicating that strain AF15561 is more
virulent in these animals (Fig. 5A). Mice inoculated with
AF15561 E2 G82R gained weight in parallel with mock-infected
mice, suggesting that an arginine at E2 residue 82 in the
AF15561 background significantly reduces CHIKV virulence.
However, mice inoculated with 181/25 E2 R82G did not exhibit
impaired weight gain, suggesting that substitution of a glycine
at E2 residue 82 in strain 181/25 is not sufficient to recapitulate
the virulent phenotype.
To determine the effect of E2 residue 82 on CHIKV-induced
arthritis, we assessed swelling of the left and right feet at 1, 3, 5, and
7 days postinoculation (Fig. 5B). At 3, 5, and 7 days postinocula-
tion, mice infected with virus strain AF15561 exhibited significant
swelling of the left feet. No swelling was observed in the uninocu-
lated feet of any of the animals. Inoculation with AF15561 E2
G82R resulted in reduced swelling in the left hind limb at 3 and 5
days postinoculation relative to AF15561, whereas inoculation
with 181/25 E2 R82G only modestly increased swelling at 5 days
postinoculation relative to 181/25. Together, these data suggest
that a glycine at E2 residue 82 is necessary but not sufficient for full
virulence of strain AF15561, as assessed by weight gain and foot
swelling.
To determine whether E2 residue 82 influences the magnitude
of pathological injury, left hind limbs of infected mice were pro-
cessed for histology and assigned a pathology score based on his-
tologic changes (Fig. 6). Tissue damage appeared more severe for
mice infected with virus strain AF15561 than for mice infected
with virus strain 181/25 at day 7 postinoculation (Fig. 6A and B).
In particular, there was slightly more inflammation and necrosis
in the metatarsal muscles of AF15561-infected mice compared to
those of 181/25-infected mice. However, the levels of myositis and
tendonitis induced by these strains were comparable. Substitution
of an arginine at E2 82 in the AF15561 strain led to reduced tissue
damage, inflammation, and necrosis compared to mice inocu-
lated with the parental AF15561 strain (Fig. 6B). More dramati-
cally, substitution of a glycine at this residue in the 181/25 strain
led to consistently more inflammation and necrosis of the meta-
tarsal muscle as well as more severe tendonitis in the hind limb
relative to the hind limbs of 181/25-infected mice. These data
suggest that E2 residue 82 modulates CHIKV-induced disease and
that a glycine at this residue is sufficient to mediate tissue injury in
CHIKV-infected mice.
CHIKV titers in the spleen and serum are influenced by E2
residue 82. To determine whether differences in virus-induced
pathology are a consequence of differences in viral replication,
mice were inoculated subcutaneously in the left rear footpad with
103 PFU of virus strain 181/25, AF15561, 181/25 E2 R82G, or
FIG 4 An arginine at E2 residue 82 confers greater dependence on glycosaminoglycans. (A) CHO-K1 and CHO-pgsA745 cells were adsorbed with virus strain
AF15561, 181/25, AF1561 E2 G82R, or 181/25 E2 R82G at an MOI of 10 PFU/cell and incubated for 24 h. Wild-type (WT) CHIKV or variant strains containing
substitutions at E2 residue 82 were tested. The cells were stained with CHIKV-specific antiserum and DAPI to detect nuclei and imaged by fluorescence
microscopy. Results are presented as percent infected cells for triplicate experiments normalized to the values for parental CHO-K1 cells. Error bars indicate
standard errors of the means. (B) Strains AF15561, 181/25, AF1561 E2 G82R, and 181/25 E2 R82G were treated with BSA at 1,000 g/ml or heparin at the
concentrations shown for 30 min and adsorbed to Vero cells at an MOI of 2.5 PFU/cell. After incubation for 24 h, cells were stained with CHIKV-specific
antiserum and DAPI to detect nuclei and imaged by fluorescence microscopy. Results are presented as percent infected cells for triplicate experiments normalized
to the values for mock-treated virus. Error bars indicate standard errors of the means. (C) The virus strains shown at 5  109 genome copies each were incubated
with heparin-conjugated or unconjugated agarose beads for 30 min, resolved by SDS-PAGE, and detected by immunoblotting with CHIKV E2-specific MAb
(left). Twenty-five percent of input virus is shown as a control. The percentage of virus bound to beads was quantified by optical densitometry for triplicate
experiments (right). Error bars indicate standard deviations. Values that are significantly different, as determined by Student’s t test (A and C) and Kruskal-Wallis
analysis followed by Dunn’s posthoc test (B), are indicated by asterisks as follows: , P 	 0.05; , P 	 0.01; , P 	 0.001.
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AF15561 E2 G82R. Tissues were harvested at 1, 3, and 5 days
postinoculation, and viral titers were determined by plaque assay
(Fig. 7). At 1 day postinoculation, all viruses produced equivalent
titers in the left and right hind limbs (Fig. 7A). However, virus
strain AF15561 produced higher titers in the spleen and serum
relative to virus strain 181/25. The titers of strain AF15561 E2
G82R were reduced in the spleen and serum compared to those of
strain AF15561 at 1 day postinoculation, and strain 181/25 E2
R82G produced higher titers in the spleen and serum compared to
those of strain 181/25, although this difference was not statistically
significant. These data suggest that a glycine at E2 residue 82 con-
tributes to higher viral titers in the spleen and serum at early times
postinoculation.
By 3 days postinoculation, all viruses produced comparable
titers in the left ankle, but strain AF15561 replicated to signifi-
cantly higher titers in the left quadriceps and right ankle relative to
strain 181/25 (Fig. 7B). However, this difference in replication did
not segregate with E2 residue 82, as mice inoculated with AF15561
E2 G82R displayed higher viral titers in the left quadriceps and
right ankle relative to 181/25 E2 R82G. Similarly, higher titers of
AF15561 E2 G82R were detected in the right quadriceps and se-
rum relative to 181/25 E2 R82G. In the spleen, we observed a trend
similar to the day 1 time point with AF15561 E2 G82R producing
lower titers in that organ relative to AF15561, and 181/25 E2 R82G
producing slightly higher titers relative to 181/25.
By 5 days postinoculation, no virus was detected in the serum.
In the left and right quadriceps, titers of virus strain AF15561 E2
G82R were higher relative to those of strain AF15561. In addition,
titers of virus strain 181/25 were higher in these tissues relative to
those of 181/25 E2 R82G. These data suggest that an arginine at E2
residue 82 correlates with higher viral titers in the quadriceps
muscles at later times postinoculation. In contrast, viruses con-
taining a glycine at E2 82 produced higher titers in the spleen at
earlier times postinoculation. Thus, residue 82 in the E2 glycopro-
tein contributes to either viral dissemination to or replication
within the hind limbs and spleen and influences establishment of
viremia.
A glycine at E2 residue 82 is selected in the spleens of CHIKV-
infected mice. Since high mutation rates are associated with rep-
lication of positive-sense RNA viruses, we determined the se-
quences of viral isolates from CHIKV-infected mice to assess the
stability of the engineered mutations. RNA was isolated from the
spleens of CHIKV-infected mice at 1 day postinoculation, cDNA
was generated, and sequences of the E2 open reading frame from
multiple clones were determined. Of the clones derived from mice
inoculated with strain AF15561 E2 G82R, 21 of 23 clones (91%)
encoded a glycine at E2 residue 82. In contrast, only 1 of 7 (14%)
of the clones derived from mice inoculated with strain AF15561
encoded an arginine at this position. Viral RNA could not be re-
covered from the spleens of animals infected with virus strain
181/25 at this early time point, which precluded sequence analysis.
To confirm that these mutations were not present in the viral
inocula, RNA was isolated from virus stocks, cDNA was gener-
ated, and E2 sequences were determined. Of the 20 clones se-
quenced from each virus stock, all encoded the engineered resi-
dues across the E2 open reading frame. These results suggest that
FIG 5 CHIKV E2 residue 82 modulates virus-induced pathology. C57BL/6J mice (20 to 22 days old) were inoculated with 103 PFU of CHIKV strain AF15561,
181/25, AF1561 E2 G82R, or 181/25 E2 R82G in the left rear footpad. (A) Mice were weighed at 24-h intervals postinoculation. Results are presented as the mean
percent starting weight (weight on day 0). Error bars indicate standard deviations. The number of mice at different time points follow: day 0 to day 1 (D0-D1),
n 
 17; D2-D3, n 
 15; D4-D5, n 
 8; D6-D7, n 
 3. (B) Swelling of the left and right hind feet was quantified using calipers at the times shown (in days). Error
bars indicate standard deviations. The number of mice at different time points follow: D1, n 
 2; D3, n 
 7; D5, n 
 5; D7, n 
 3. Values that are significantly
different as determined by ANOVA followed by Bonferroni’s posthoc test are indicated by asterisks as follows: , P 	 0.05; , P 	 0.01; , P 	 0.001.
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a glycine at E2 82 is preferentially selected early in CHIKV infec-
tion in the spleen, but a residual population of isolates with an
arginine at this position is maintained.
DISCUSSION
CHIKV causes both an acute and chronic disease characterized by
debilitating joint pain and inflammation (1, 2). However, the viral
and host determinants responsible for CHIKV disease have not
been fully defined. Additionally, mechanisms of pathogenesis for
arthritogenic alphaviruses like CHIKV are not completely under-
stood. CHIKV strain 181/25, which was isolated following serial
passage in mammalian cell culture, differs from its closest known
parental strain, AF15561, at 5 synonymous and 5 nonsynonymous
nucleotide positions. One nonsynonymous polymorphism, G82R
in the E2 attachment protein, influences interactions with GAGs
(38) and attenuates virulence in some mouse models (31, 45). In
this study, we demonstrate a role for E2 residue 82 in the differ-
ential infection of mammalian and mosquito cells and in CHIKV-
induced musculoskeletal disease. Viruses containing a glycine at
E2 82 replicated to higher titers in lymphoid tissues and estab-
lished higher levels of viremia. Moreover, these viruses induced
greater pathological injury, including inflammation and necrosis,
in joint-associated tissues compared with viruses containing an
arginine at this position. Data presented here expand our knowl-
edge of how CHIKV E2 residue 82 influences virus-cell interac-
tions and provide new information about the function of this
residue in vivo.
Our results along with previously published data (31, 38, 45)
indicate that an arginine at E2 residue 82 enhances utilization of
GAGs by CHIKV to infect cultured cells and attenuates the virus
in mice. However, it is not clear how an increase in GAG depen-
dence leads to attenuation of CHIKV. For other alphaviruses, such
FIG 6 An arginine at E2 residue 82 diminishes CHIKV-induced arthritis. C57BL/6J mice (20 to 22 days old) were inoculated with PBS or 103 PFU of virus strain
AF15561, 181/25, AF1561 E2 G82R, or 181/25 E2 R82G in the left rear footpad. At day 7 postinoculation, mice were euthanized and perfused with 4% PFA.
Consecutive 5-m sections of the left hind limb were stained with H&E. (A) Representative sections of three mice per group are shown for mock-infected mice
or mice inoculated with the parental strains and the reciprocal E2 82 variant strains. Bars, 50 m. (B) H&E-stained sections were scored for histological evidence
of inflammation and necrosis in the metatarsal muscle and tendonitis. Results are expressed as pathology score of tissues from individual animals. Horizontal
black lines indicate mean pathology score. Scores were assigned based on the following scale: 0, no lesions; 1, minimal, 0 to 24% of tissue affected; 2, mild, 25 to
49% of tissue affected; 3, moderate, 50 to 75% of tissue affected; 4, marked, 75% of tissue affected.
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as Sindbis virus and Venezuelan equine encephalitis virus, higher-
affinity interactions with GAGs prevent viral spread to sites of
secondary replication or facilitate viral clearance from the blood-
stream (34, 55, 56). We found that CHIKV strains containing an
arginine at E2 82 produce lower titers at sites of secondary repli-
cation, including the spleen, and reduced viremia in immuno-
competent mice. These findings are consistent with those ob-
tained by Gardner et al. using a similar mouse model (45). Thus, it
appears that GAG-dependent strains of CHIKV disseminate less
efficiently, are cleared more rapidly, or perhaps both.
E2 residue 82 may also contribute to differences in tissue tro-
pism by both GAG-dependent and GAG-independent mecha-
nisms. Differential distribution and levels of GAGs throughout
the body may influence targeting of GAG-dependent viruses to
specific tissues or alter the capacity of these viruses to interact with
specific cell types. Virus strains 181/25 and AF15561 differ in GAG
dependence but not to the extent observed for strain 181/25 and
other clinical isolates (37, 38, 45). Strain 181/25 infectivity in
CHO-pgsA745 cells, which lack all GAGs, was decreased less than
4-fold relative to strain AF15561. In addition, the 50% inhibitory
concentration (IC50) of heparin inhibition for strains 181/25 and
AF15561 were comparable (9.4 and 10.8 g/ml, respectively).
These data suggest that additional mechanisms underlie the atten-
uation of strain 181/25. Since E2 82 is solvent exposed and lies
within a putative receptor-binding domain of E2 (27), it is possi-
ble that this residue participates in interactions with cellular re-
ceptors other than GAGs. Substituting AF15561 E2 Gly82 with an
arginine enhances infectivity in Vero cells relative to strain
AF15561, likely by promoting interactions with GAGs or other cell
surface moieties to mediate attachment. Enhanced viral attach-
ment to the cell surface would facilitate more rapid internalization
of the virus and consequent infection. However, infectivity of
AF15561 E2 G82R was also significantly greater than that observed
for the 181/25 strain in Vero cells, although both strains bound
heparin-conjugated agarose beads to a similar extent. Further-
more, substituting AF15561 E2 Gly82 with an arginine only mod-
estly enhanced binding to Vero cells. Thus, these findings suggest
that an arginine at this residue in the AF15561 background pro-
vides a replication advantage in mammalian cell culture in addi-
tion to GAG engagement and attachment to host cells.
As early as 1 day postinoculation of strain AF15561 E2 G82R,
nucleotide sequences of most isolates detected in the spleens of
infected mice encode a glycine at E2 residue 82. Reversion was also
observed by Gorchakov et al. (31) in which 100% isolates in blood
encode a glycine at E2 82 by 3 days postinoculation. In contrast,
following inoculation with the E2 T12I variant, only 22% of iso-
lates encoded a threonine at E2 residue 12 (31). E2 82 may mediate
viral tropism specifically in lymphoid tissues early in infection,
and the presence of an arginine at this residue may limit the ca-
pacity of the virus to replicate in lymphoid cells. Consistent with
this idea, lower levels of viral RNA were detected in the popliteal
lymph nodes of mice inoculated with viruses containing an argi-
nine at E2 82 (data not shown). The rapid selection of a glycine at
this residue may explain the higher titers of virus strains 181/25
and AF15561 E2 G82R in the spleens and other tissues of infected
mice at later times postinoculation and might support a role for
this site early in infection. Although viral isolates from the spleens
of AF15561-infected mice encoded a glycine at E2 82, the popula-
tion was not homogeneous, as one clone encoded an arginine at
this residue. These data suggest that selection at this position is not
absolute in vivo.
Residues in E2 regulate virion stability by influencing the fold-
ing of the protein and by mediating interactions with the E1 and
capsid proteins on the virion surface (57–61). Therefore, changes
in E2, such as the nonconservative G82R substitution, may alter
the stability of the CHIKV virion as demonstrated for other alpha-
viruses (57–61). When the E2 Arg82 residue was modeled into the
crystal structure of the CHIKV E1/E2 heterodimer (Protein Data
Bank [PDB] accession no. 3N42 [27]), this residue closely apposes
Glu79, which likely results in the formation of a salt bridge be-
tween the cationic guanidinium group of arginine and the anionic
carboxylate group of glutamate (data not shown). The formation
FIG 7 Viral loads following inoculation of parental strains and the reciprocal
E2 82 variant strains. C57BL/6J mice (20 to 22 days old) were inoculated with
PBS or 103 PFU of virus strain AF15561, 181/25, AF1561 E2 G82R, or 181/25
E2 R82G in the left rear footpad. At days 1, 3, and 5 postinoculation, mice were
euthanized, their ankles, quadriceps (Quad), and spleens were excised, and
serum was collected. Viral titers in tissue and serum homogenates were deter-
mined by plaque assay using BHK-21 cells. Results are expressed as the mean
PFU/gram (tissue) or PFU/ml (serum). Error bars indicate standard errors of
the means. Dashed lines indicate the limit of detection. The number of mice at
different time points follow: D1, n 
 5; D3, n 
 7; D5, n 
 5. Values that are
significantly different as determined by ANOVA followed by Bonferroni’s
posthoc test are indicated by asterisks and bars as follows: , P 	 0.05; , P 	
0.01; , P 	 0.001.
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of this salt bridge may stabilize the E2 protein and, in turn, pro-
mote CHIKV infectivity in cell culture and at sites of initial repli-
cation but limit dissemination to sites of secondary replication.
Beyond viral attachment and tissue tropism, E2 82 may con-
tribute to host responses to CHIKV early in infection. Although
there were significant differences in swelling and pathology in the
left hind limb, titers produced at this site by strains that vary solely
at E2 82 were comparable. These data support the hypothesis that
differences in pathological injury produced by CHIKV strains
with an E2 residue polymorphism result from differences in im-
mune and inflammatory responses. Such responses could be tis-
sue specific and dependent upon replication efficiency in the dis-
crete cell subsets that are targeted within those tissues.
Concordant with this hypothesis, relative to the virulent CHIKV
LR strain, LR E2 Arg82 induces lower levels of proinflammatory
cytokines and chemokines (45). Our data suggest that E2 residue
82 also modulates the induction of necrotic pathways that con-
tribute to differences in swelling elicited by these viruses during
infection. Despite similar levels of myositis and tendonitis in-
duced by these strains, viruses containing E2 Arg82 induced less
necrosis in the hind limb metatarsal muscle than viruses contain-
ing E2 Gly82. In mice deficient for alpha/beta interferon (IFN-
/) receptors or the signal transducer and activator of tran-
scription factor 1 (STAT1) signal transducer, similar levels of
inflammatory infiltrates were observed in the hind limbs follow-
ing infection with CHIKV strains LR and 181/25, despite reduced
swelling in mice infected with strain 181/25 (37). These data sug-
gest a correlation between induction of necrotic pathways and
events that contribute to swelling in the infected host, which may
occur independently of immune cell infiltration.
Our study demonstrates that a glycine at E2 82 is required for
virulence in the AF15561 background but not sufficient to confer
virulence to the attenuated 181/25 strain. Substituting 181/25 E2
Arg82 with glycine failed to recapitulate the virulent phenotype, as
assessed by weight gain and footpad swelling. However, introduc-
ing a glycine at E2 82 was sufficient to induce histopathological
injury in the hind limbs of infected mice to levels induced by the
parental AF15561 strain. Therefore, the effects of this residue are
dependent on the genetic background in which the polymorphism
is present. Accordingly, substitution of AF15561 E2 Thr12 with
isoleucine from strain 181/25, which infects mammalian cells
more efficiently, decreased infectivity to levels less than those ob-
served for AF15561. This substitution was demonstrated previ-
ously to contribute to 181/25 attenuation (31) but was not iden-
tified in our study in which we used infectivity in mammalian cells
as an in vitro correlate of virulence to screen viral variants. There-
fore, additional polymorphisms displayed by strains AF15561 and
181/25 likely contribute to attenuation of 181/25 in this mouse
model of CHIKV disease.
An arginine at E2 residue 82 does not mediate enhancement of
infectivity in mosquito cells as in mammalian cells. These data
suggest a GAG-independent function for this residue in inverte-
brate cells. Several mosquito species express the enzymes capable
of synthesizing GAGs (62), but a thorough characterization of
GAGs expressed by C6/36 cells has not been reported. Addition-
ally, GAGs are present on the surfaces of midgut and salivary gland
cells of certain mosquito species (62, 63), but it is not clear
whether these molecules contribute to CHIKV infection in the
invertebrate host. In contrast to mammalian cells, substituting
181/25 E2 Arg82 with glycine enhances infection of C6/36 cells.
This enhancement might result from disrupting interactions with
negatively charged GAGs or promoting different or enhanced in-
teractions with other mosquito cell factors either at the cell surface
or during later steps in infection. The former would indicate that
interactions with GAGs on the surfaces of C6/36 cells impede
CHIKV infection. We think this is not the case, as substituting
AF15561 E2 Gly82 with arginine does not substantially diminish
infection of these cells. Additional cell surface entry mediators
may or may not be the same for mammalian and mosquito hosts.
The importance of a glycine at this residue for viral fitness is evi-
denced by its high conservation among CHIKV isolates (38), sug-
gesting that it confers an advantage for replication in mosquitoes.
Understanding mechanisms of virus entry and the interactions
that promote dissemination and pathogenesis is critical for devel-
opment of pathogen-specific therapeutic and prophylactic inter-
vention strategies. Our study suggests that E2 residue 82 is a de-
terminant of infection in both mammalian and mosquito cells and
defines a role for E2 residue 82 in GAG engagement and CHIKV
virulence in vivo. We demonstrate that viruses containing E2
Arg82 display enhanced infectivity in mammalian cells, while vi-
ruses containing E2 Gly82 display enhanced infectivity in mos-
quito cells. The enhancement provided by an arginine at E2 82 was
only partly attributable to increased binding, suggesting that this
residue promotes interactions with other cell surface molecules or
influences steps in the virus life cycle following attachment. In
infected mice, viruses encoding an arginine at E2 residue 82 ex-
hibit defects in replication in lymphoid tissues, establishment of
viremia, and production of pathological injury in joint-associated
muscle. A glycine at E2 82 is under strong selective pressure in the
spleens of CHIKV-infected mice, but this residue was not static, as
an arginine was also selected at low frequency. Our findings sup-
port new functions for E2 residue 82 in host-specific and GAG-
independent processes and in the development of joint swelling
through necrosis-mediated events. Future studies to understand
mechanisms by which E2 residue 82 influences CHIKV tropism
and host responses during infection will reveal both viral and host
targets to restrict infection and diminish disease.
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